Summary
Obesity affects 150 million people in Europe and 650 million worldwide. People with obesity are at a greater risk of health complications like heart disease, diabetes and cancer.
The aim of the SOPHIA project is to improve our ability to predict who will experience which complications, and who will respond best to different obesity treatments. Currently, this is not possible. Part of the project will focus in particular on the relationship between type 1 diabetes and weight, as a large proportion of people with type 1 diabetes is overweight or has obesity.
SOPHIA will link up and analyse data from different cohorts of people with obesity, and carry out in-depth qualitative studies with patients to identify their perceptions and perspectives on obesity diagnosis and treatment.
This will hopefully deliver insights on the variables that predict the risk of complications and responses to treatment.
People living with obesity will be involved in all aspects of the project via a Patient Advisory Board. Ultimately, the project results should provide the basis for treatment pathways that are accepted by patients, healthcare systems, researchers and clinicians alike.
More broadly, the project hopes to change the narrative around obesity, to make it more patient-centric and equitable and to underline that it is a chronic disease, not something people choose to live with.
Achievements & News
December 2023
IMI project SOPHIA has developed an online tool that allows patients and doctors to predict weight loss following bariatric surgery.
March 2023
IMI project SOPHIA is shedding new light on the mechanisms that can cause type 2 diabetes in obesity, as well...
The outdated way we treat obesity has to change, according to researchers from one of IMI’s newest projects, SOPHIA.###
According to project coordinator Prof. Carel le Roux of University College Dublin, obesity treatment has traditionally involved creating a calorie deficit using diet and exercise, an approach that has not always proved effective. It can even makes things worse. Yet despite advances in pharmacological and surgical treatments in the last decade, many healthcare professionals still lack adequate training in new approaches. Moreover, obesity is not considered a disease in many countries, meaning that resources dedicated to treating it are minimal.
‘This means that we are treating the disease with basic and even outdated treatments that cause temporary weight loss, leading to long-term implications like untoward changes in body composition, weight regain, increased duration of patients living with obesity-related complications, stress and depression, and diminished quality of life,’ explains Prof. le Roux.
We currently don’t know which patients will develop complications secondary to their obesity, and who will respond to the new and expensive treatments. SOPHIA has set out to identify these predictors so that we can improve the quality of care. It will be the first project of this scale to address this important question, says Prof. le Roux.
Find out more
- Read the interview in full
Participants
Show participants on mapEFPIA companies
- Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- Medtronic International Trading SARL, Tolochenaz, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Assistance Publique Hopitaux De Paris, Paris, France
- Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- Consiglio Nazionale Delle Ricerche, Roma, Italy
- Dasman Research Education And Training Company, Sharq, Kuwait
- Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- Fundacio Institut D'Investigacio Biomedica De Girona Doctor Josep Trueta, Salt, Spain
- George Washington University Corporation, Washington Dc, United States
- Goeteborgs Universitet, Gothenburg, Sweden
- Katholieke Universiteit Leuven, Leuven, Belgium
- Lunds Universitet, Lund, Sweden
- Maccabi Sheirutei Briut Foundation, Tel Aviv, Israel
- SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
- The European Association For The Study Of Obesity - Ireland Company Limited By Guarantee, Dublin, Ireland
- The University Of Exeter, Exeter, United Kingdom
- Universita Cattolica Del Sacro Cuore, Milan, Italy
- Universitaet Ulm, Ulm, Germany
- Universiteit Maastricht, Maastricht, Netherlands
- University College Cork - National University Of Ireland, Cork, Cork, Ireland
- University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
- University Of Bristol, Bristol, United Kingdom
- University Of Dundee, Dundee, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Atturos Limited, Limerick Clare, Ireland
- Lipotype, Dresden, Germany
- Metabolon GMBH, Potsdam, Germany
- Third-I, Vilvoorde, Belgium
Associated partners
- Breakthrough T1d, New York, United States
- Obesity Action Coalition Inc, Tampa, United States
- T1d Exchange Inc, Boston, United States
Third parties
- Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
- Obesitas Nederland BV, Huis Ter Heide, Netherlands
- Universidad De Navarra, Pamplona, Spain
- Universita Degli Studi Di Roma Tor Vergata, Rome, Italy
| Participants | |
|---|---|
| Name | EU funding in € |
| Atturos Limited | 2 727 |
| Centre Hospitalier Regional Et Universitaire De Lille | 299 998 |
| Consiglio Nazionale Delle Ricerche | 255 000 |
| Eberhard Karls Universitaet Tuebingen | 300 000 |
| Erasmus Universitair Medisch Centrum Rotterdam | 300 000 |
| Fundacio Institut D'Investigacio Biomedica De Girona Doctor Josep Trueta | 256 250 |
| George Washington University Corporation | 299 999 |
| Goeteborgs Universitet | 570 000 |
| Katholieke Universiteit Leuven | 437 500 |
| Lipotype | 300 000 |
| Lunds Universitet | 855 000 |
| Metabolon GMBH | 464 134 |
| SIB Institut Suisse De Bioinformatique, CH-660-0733998-3 | 850 000 |
| The European Association For The Study Of Obesity - Ireland Company Limited By Guarantee | 25 000 |
| The University Of Exeter | 299 925 |
| Third-I | 300 000 |
| Universita Cattolica Del Sacro Cuore | 297 500 |
| Universitaet Ulm | 166 844 |
| Universiteit Maastricht | 288 798 |
| University College Cork - National University Of Ireland, Cork | 20 000 |
| University College Dublin, National University Of Ireland, Dublin | 1 594 826 |
| Third parties | |
| Name | Funding in € |
| Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina | 43 750 |
| Universita Degli Studi Di Roma Tor Vergata | 73 750 |
| Total Cost | 8 301 001 |
Carel W Le Roux
University College Dublin, National University Of Ireland, Dublin